Symbols / NVCT Stock $8.82 +2.80% Nuvectis Pharma, Inc.
NVCT (Stock) Chart
About
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Stock Fundamentals
Scroll to Statements| Market Cap | 233.66M | Enterprise Value | 202.02M | Income | -28.87M | Sales | — | Book/sh | 0.72 | Cash/sh | 1.19 |
| Dividend Yield | — | Payout | 0.00% | Employees | 13 | IPO | — | P/E | — | Forward P/E | -9.19 |
| PEG | — | P/S | — | P/B | 12.30 | P/C | — | EV/EBITDA | — | EV/Sales | — |
| Quick Ratio | 2.38 | Current Ratio | 2.38 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -1.32 | EPS next Y | -0.96 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-05 | ROA | -68.50% | ROE | -188.03% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 26.49M | Shs Float | 15.44M | Short Float | 10.18% |
| Short Ratio | 25.17 | Short Interest | — | 52W High | 11.52 | 52W Low | 5.55 | Beta | -0.21 | Avg Volume | 57.88K |
| Volume | 48.14K | Target Price | $16.80 | Recom | None | Prev Close | $8.58 | Price | $8.82 | Change | 2.80% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$16.80
Mean price target
2. Current target
$8.82
Latest analyst target
3. DCF / Fair value
$-4.64
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.82
Low
$10.00
High
$20.00
Mean
$16.80
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-04 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-04-30 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-04-02 | init | Maxim Group | — → Buy | $17 |
| 2025-03-17 | init | Laidlaw & Co. | — → Buy | $19 |
| 2025-02-25 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-08-06 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2024-05-08 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2023-09-15 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2023-03-07 | reit | HC Wainwright & Co. | — → Buy | $21 |
| 2023-02-10 | reit | HC Wainwright & Co. | — → Buy | $21 |
| 2022-07-13 | init | Ladenburg Thalmann | — → Buy | $21 |
| 2022-05-10 | main | HC Wainwright & Co. | — → Buy | $21 |
| 2022-03-02 | init | HC Wainwright & Co. | — → Buy | $14 |
- Three cancer studies put Nuvectis drug NXP900 on AACR agenda - Stock Titan ue, 31 Mar 2026 07
- Technical Reactions to NVCT Trends in Macro Strategies - Stock Traders Daily hu, 16 Apr 2026 11
- Will Nuvectis Pharma (NVCT) Stock Recover Soon | Price at $7.65, Up 1.19% - Community Sell Signals - UBND thành phố Hải Phòng Mon, 06 Apr 2026 07
- We Think Nuvectis Pharma (NASDAQ:NVCT) Can Afford To Drive Business Growth - simplywall.st Fri, 09 Jan 2026 08
- Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights - GlobeNewswire Wed, 11 Feb 2026 08
- Nuvectis Pharma Initiates Phase 1b Study of NXP900 in Combination with Osimertinib for EGFRmut+ NSCLC Patients - Quiver Quantitative Wed, 17 Dec 2025 08
- Why Nuvectis Pharma, Inc. (NVCT) is Surging in 2025 - Yahoo Finance Wed, 30 Apr 2025 07
- NVCT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI Sat, 28 Feb 2026 05
- Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail hu, 12 Feb 2026 08
- Nuvectis Pharma: Still Interesting, But Still Too Risky To Jump In - Seeking Alpha Wed, 18 Jun 2025 07
- symbol__ Stock Quote Price and Forecast - CNN ue, 26 Mar 2024 19
- Nuvectis Pharma, Inc. Provides Update on NXP900 Clinical Program and Q3 2025 Financial Results - Quiver Quantitative ue, 04 Nov 2025 08
- A US$22m Market Cap Boost Pleasing ToNuvectis Pharma Insiders - simplywall.st hu, 30 Oct 2025 07
- Nuvectis Pharma (NVCT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat Wed, 09 Jul 2025 19
- NVCT Forecast — Price Prediction for 2026. Should I Buy NVCT? - Intellectia AI ue, 20 May 2025 11
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
27.57
+38.93%
|
19.85
-13.32%
|
22.90
+19.04%
|
19.23
|
| Research And Development |
|
18.15
+40.52%
|
12.92
-16.01%
|
15.38
+16.28%
|
13.23
|
| Selling General And Administration |
|
9.42
+35.96%
|
6.93
-7.82%
|
7.52
+25.14%
|
6.01
|
| General And Administrative Expense |
|
9.42
+35.96%
|
6.93
-7.82%
|
7.52
+25.14%
|
6.01
|
| Salaries And Wages |
|
2.42
+15.78%
|
2.09
-9.01%
|
2.30
+30.87%
|
1.76
|
| Other Gand A |
|
6.40
+51.25%
|
4.23
-3.31%
|
4.38
+42.67%
|
3.07
|
| Total Expenses |
|
27.57
+38.93%
|
19.85
-13.32%
|
22.90
+19.04%
|
19.23
|
| Operating Income |
|
-27.57
-38.93%
|
-19.85
+13.32%
|
-22.90
-19.04%
|
-19.23
|
| Total Operating Income As Reported |
|
-27.57
-38.93%
|
-19.85
+13.32%
|
-22.90
-19.04%
|
-19.23
|
| EBITDA |
|
-27.57
-38.93%
|
-19.85
+13.32%
|
-22.90
-19.04%
|
-19.23
|
| Normalized EBITDA |
|
-27.57
-38.93%
|
-19.85
+13.32%
|
-22.90
-19.04%
|
-19.23
|
| EBIT |
|
-27.57
-38.93%
|
-19.85
+13.32%
|
-22.90
-19.04%
|
-19.23
|
| Net Income |
|
-26.44
-39.17%
|
-19.00
+14.65%
|
-22.26
-16.64%
|
-19.09
|
| Pretax Income |
|
-26.44
-39.17%
|
-19.00
+14.65%
|
-22.26
-16.64%
|
-19.09
|
| Net Non Operating Interest Income Expense |
|
1.13
+33.65%
|
0.85
+32.97%
|
0.64
+327.52%
|
0.15
|
| Net Interest Income |
|
1.13
+33.65%
|
0.85
+32.97%
|
0.64
+327.52%
|
0.15
|
| Interest Income Non Operating |
|
1.13
+33.65%
|
0.85
+32.97%
|
0.64
+327.52%
|
0.15
|
| Interest Income |
|
1.13
+33.65%
|
0.85
+32.97%
|
0.64
+327.52%
|
0.15
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-26.44
-39.17%
|
-19.00
+14.65%
|
-22.26
-16.64%
|
-19.09
|
| Net Income From Continuing Operation Net Minority Interest |
|
-26.44
-39.17%
|
-19.00
+14.65%
|
-22.26
-16.64%
|
-19.09
|
| Net Income From Continuing And Discontinued Operation |
|
-26.44
-39.17%
|
-19.00
+14.65%
|
-22.26
-16.64%
|
-19.09
|
| Net Income Continuous Operations |
|
-26.44
-39.17%
|
-19.00
+14.65%
|
-22.26
-16.64%
|
-19.09
|
| Normalized Income |
|
-26.44
-39.17%
|
-19.00
+14.65%
|
-22.26
-16.64%
|
-19.09
|
| Net Income Common Stockholders |
|
-28.87
-51.95%
|
-19.00
+14.65%
|
-22.26
-16.64%
|
-19.09
|
| Otherunder Preferred Stock Dividend |
|
2.43
|
0.00
|
—
|
—
|
| Diluted EPS |
|
—
|
-1.11
+22.38%
|
-1.43
+5.30%
|
-1.51
|
| Basic EPS |
|
—
|
-1.11
+22.38%
|
-1.43
+5.30%
|
-1.51
|
| Basic Average Shares |
|
—
|
17.11
+10.01%
|
15.56
+22.90%
|
12.66
|
| Diluted Average Shares |
|
—
|
17.11
+10.01%
|
15.56
+22.90%
|
12.66
|
| Diluted NI Availto Com Stockholders |
|
-28.87
-51.95%
|
-19.00
+14.65%
|
-22.26
-16.64%
|
-19.09
|
| Insurance And Claims |
|
0.60
-1.16%
|
0.61
-28.03%
|
0.84
-28.83%
|
1.18
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
19.18
|
| Current Assets |
|
19.18
|
| Cash Cash Equivalents And Short Term Investments |
|
19.13
|
| Cash And Cash Equivalents |
|
19.13
|
| Other Current Assets |
|
0.06
|
| Total Non Current Assets |
|
0.00
|
| Non Current Deferred Assets |
|
—
|
| Total Liabilities Net Minority Interest |
|
6.98
|
| Current Liabilities |
|
6.98
|
| Payables And Accrued Expenses |
|
3.19
|
| Payables |
|
2.77
|
| Accounts Payable |
|
2.77
|
| Other Payable |
|
—
|
| Current Accrued Expenses |
|
0.41
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
3.80
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
| Preferred Securities Outside Stock Equity |
|
—
|
| Stockholders Equity |
|
12.20
|
| Common Stock Equity |
|
12.20
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Share Issued |
|
17.42
|
| Ordinary Shares Number |
|
17.42
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
66.45
|
| Retained Earnings |
|
-54.24
|
| Total Equity Gross Minority Interest |
|
12.20
|
| Total Capitalization |
|
12.20
|
| Working Capital |
|
12.20
|
| Invested Capital |
|
12.20
|
| Net Tangible Assets |
|
12.20
|
| Tangible Book Value |
|
12.20
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-16.01
-30.72%
|
-12.25
+23.24%
|
-15.95
-17.66%
|
-13.56
|
| Cash Flow From Continuing Operating Activities |
|
-16.01
-30.72%
|
-12.25
+23.24%
|
-15.95
-17.66%
|
-13.56
|
| Net Income From Continuing Operations |
|
-26.44
-39.17%
|
-19.00
+14.65%
|
-22.26
-16.64%
|
-19.09
|
| Stock Based Compensation |
|
6.03
+24.17%
|
4.86
+3.25%
|
4.71
+175.63%
|
1.71
|
| Change In Working Capital |
|
4.40
+132.24%
|
1.90
+18.36%
|
1.60
-58.08%
|
3.82
|
| Change In Payables And Accrued Expense |
|
3.05
+1907.24%
|
0.15
-87.82%
|
1.25
-69.86%
|
4.14
|
| Change In Accrued Expense |
|
-0.72
-270.59%
|
0.42
-69.36%
|
1.39
-39.41%
|
2.29
|
| Change In Payable |
|
3.78
+1483.15%
|
-0.27
-96.40%
|
-0.14
-107.51%
|
1.85
|
| Change In Account Payable |
|
3.78
+1483.15%
|
-0.27
-96.40%
|
-0.14
-107.51%
|
1.85
|
| Change In Other Working Capital |
|
1.35
-23.15%
|
1.76
+24.06%
|
1.42
-27.37%
|
1.95
|
| Change In Other Current Assets |
|
-0.00
+93.33%
|
-0.01
-104.25%
|
0.35
+209.97%
|
-0.32
|
| Investing Cash Flow |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Financing Cash Flow |
|
29.11
+149.79%
|
11.65
-22.75%
|
15.09
-45.75%
|
27.81
|
| Cash Flow From Continuing Financing Activities |
|
29.11
+149.79%
|
11.65
-22.75%
|
15.09
-45.75%
|
27.81
|
| Net Common Stock Issuance |
|
31.21
+159.31%
|
12.04
+127.57%
|
5.29
-83.41%
|
31.88
|
| Proceeds From Stock Option Exercised |
|
—
|
0.00
-100.00%
|
11.19
|
0.00
|
| Net Other Financing Charges |
|
-2.10
-449.74%
|
-0.38
+72.60%
|
-1.39
+65.74%
|
-4.07
|
| Changes In Cash |
|
13.10
+2309.27%
|
-0.59
+31.60%
|
-0.87
-106.08%
|
14.25
|
| Beginning Cash Position |
|
18.53
-3.10%
|
19.13
-4.34%
|
19.99
+248.19%
|
5.74
|
| End Cash Position |
|
31.63
+70.69%
|
18.53
-3.10%
|
19.13
-4.34%
|
19.99
|
| Free Cash Flow |
|
-16.01
-30.72%
|
-12.25
+23.24%
|
-15.95
-17.66%
|
-13.56
|
| Interest Paid Supplemental Data |
|
—
|
—
|
—
|
—
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
—
|
—
|
| Common Stock Issuance |
|
31.21
+159.31%
|
12.04
+127.57%
|
5.29
-83.41%
|
31.88
|
| Issuance Of Capital Stock |
|
31.21
+159.31%
|
12.04
+127.57%
|
5.29
-83.41%
|
31.88
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-02-11 View
- 10-K2026-02-11 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 42025-11-06 View
- 42025-11-06 View
- 42025-11-06 View
- 8-K2025-11-04 View
- 10-Q2025-11-04 View
- 42025-10-31 View
- 42025-10-29 View
- 8-K2025-09-25 View
- 10-Q2025-08-05 View
- 8-K2025-08-05 View
- 42025-06-24 View
- 42025-06-20 View
- 8-K2025-06-13 View
- 42025-06-12 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|